Vistagen Therapeutics (NASDAQ:VTGN) announced its quarterly earnings data on Thursday. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01, Fidelity Earnings reports.
Shares of NASDAQ VTGN opened at $1.08 on Friday. The company has a market cap of $46.20 million, a PE ratio of -1.20 and a beta of -0.29. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 2.44. Vistagen Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.06. The firm’s 50-day moving average price is $1.15 and its 200-day moving average price is $0.83.
Several brokerages recently commented on VTGN. ValuEngine raised shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Chardan Capital reaffirmed a “hold” rating and set a $0.70 price target on shares of Vistagen Therapeutics in a report on Sunday, November 3rd. Maxim Group set a $4.00 price target on shares of Vistagen Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, William Blair reaffirmed a “buy” rating on shares of Vistagen Therapeutics in a report on Wednesday, October 9th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Vistagen Therapeutics presently has an average rating of “Buy” and a consensus price target of $2.35.
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Further Reading: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.